MVision AI is a cloud-based software service provider for radiotherapy treatment planning.
MVision AI helps you standardize organ-at-risk contouring and automate segmentation in radiotherapy to streamline cancer treatment planning.
MVision AI founded in 2017 by Mahmudul Hasan, Jarkko Niemelä and Saad Ullah Akram. The company is headquartered in Helsinki, Southern Finland, Finland.
MVision AI uses artificial intelligence to automate cancer treatment with an AI-powered automatic segmentation tool that helps to standardise contouring and automate segmentation to streamline the radiotherapy treatment planning workflow.
MVision’s AI segmentation models were developed by collecting image data from clinical partners. The platform has a CE-marked and FDA-cleared auto-segmentation feature for radiotherapy planning.
MVision's technology has been used to treat over 100,000 cancer patients in 14 countries, with significant wait-time reductions achieved in many facilities, including the Gainesville Department of Radiation Oncology, University of Florida.
MVision AI is backed by Voima Ventures, Icebreaker.VC, J12 Ventures, and others. The company raised $5.85M (€5.4M) in a post-seed round on Mar 23, 2023. This brings MVision's total funding to $8.25M to date.